Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes

Authors

Aurore Perrot
Thierry Facon
Torben Plesner
Saad Z Usmani
Shaji Kumar
Nizar J Bahlis
Cyrille Hulin
Robert Z Orlowski
Hareth Nahi
Peter Mollee
Karthik Ramasamy
Murielle Roussel
Arnaud Jaccard
Michel Delforge
Lionel Karlin
Bertrand Arnulf
Ajai Chari
George Wang
Niodita Gupta-Werner
Shuchita Kaila
Huiling Pei
Kathryn Matt
Katharine S Gries
Robin Carson
Fredrik Borgsten
Katja Weisel

Publication Date

5-1-2025

Journal

European Journal of Haematology

Abstract

Objectives: This final post hoc analysis evaluated patient-reported outcomes from the Phase 3 MAIA study of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) after median 64.5-month follow-up in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), including patient subgroups.

Methods: Key scales from the EORTC QLQ-C30 (global health status [GHS], physical functioning, pain, and fatigue) were assessed. Scores were evaluated every 3 months for 1 year, then every 6 months until disease progression.

Results: The intent-to-treat population (n = 737) included 46.3% frail, 35.4% 70 to < 75 years old, and 43.6% ≥ 75 years old. D-Rd-treated patients showed improvements from baseline that were sustained over 5 years in the intent-to-treat population and across subgroups by age, frailty, and bone lesions. Greater proportions of patients treated with D-Rd versus Rd achieved minimally important changes for improvement at cycle 36 (year ~3) in GHS (odds ratio, 1.84 [95% CI, 1.16-2.91]), physical functioning (1.93 [1.18-3.14]), pain (1.41 [0.90-2.22]), and fatigue (2.00 [1.24-3.23]). Greater proportions of patients with bone lesions improved with D-Rd versus Rd on GHS and physical functioning.

Conclusions: In transplant-ineligible patients with NDMM, D-Rd improved health-related quality of life over a 5-year period versus Rd.

Trial registration: ClinicalTrials.gov: NCT02252172.

Keywords

Humans, Multiple Myeloma, Quality of Life, Lenalidomide, Dexamethasone, Patient Reported Outcome Measures, Aged, Male, Female, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Middle Aged, Treatment Outcome, Aged, 80 and over, elderly, frail, health‐related quality of life, multiple myeloma, patient‐reported outcomes

DOI

10.1111/ejh.14392

PMID

39952901

PMCID

PMC11976685

PubMedCentral® Posted Date

2-14-2025

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes